Native Antigen encoded Nanoparticulate RNA Production Service

Developing effective immunogens often faces challenges such as preserving native protein conformation, achieving proper post-translational modifications, and ensuring efficient delivery of complex or membrane-bound antigens. Creative Biolabs' Native Antigen-encoded Nanoparticulate RNA Production Service directly addresses these hurdles by producing lipid nanoparticle (LNP)-formulated mRNA that encodes full-length, structurally authentic antigens. We provide an integrated solution, from sequence design and codon optimization to high-purity IVT synthesis and LNP encapsulation, that ensures in vivo expression of correctly folded, natively presented antigens. This end-to-end platform accelerates your discovery pipeline by delivering immunogens that elicit highly specific and potent immune responses, shortening development timelines for vaccines, therapeutics, and diagnostic tools.

Introduction

Lipid nanoparticle (LNP)-encapsulated mRNA technology overcomes critical hurdles in delivering native antigens for cancer immunotherapy. This platform enables in vivo production of structurally authentic, full-length proteins, including tumor-associated antigens and neoantigens, within antigen-presenting cells. The current state of Native Antigen-encoded Nanoparticulate RNA Production focuses on strategies such as nucleotide modification, targeted LNP design, and codon optimization that enhance translational fidelity, immune potency, and therapeutic safety, thereby establishing a versatile foundation for next-generation immunotherapies.

Fig.1 In vivo LNP-mRNA vaccine mechanism and antitumor immune activation.¹

Native Antigen-encoded Nanoparticulate RNA Production Service at Creative Biolabs

Our service is designed to bypass the traditional hurdles of recombinant protein expression. By delivering RNA that encodes the "native" version of your target, we allow the host's own cellular machinery to handle complex folding and post-translational modifications (PTMs). This ensures that the immune system or screening platform interacts with the antigen exactly as it appears in nature.

What we can offer

Our service offers an integrated platform for producing potent native antigen-encoded RNA nanoparticles, encompassing customized RNA engineering, advanced LNP formulation, and specialized immunogenicity design to support your vaccine and immunotherapy development.

Our Service Process

Required Starting Materials: To begin your project, please submit the target protein sequence in FASTA format, specify the desired cellular localization (such as secreted or membrane-bound), and indicate the intended application, including whether it is for animal immunization or in vitro screening.

Key Steps:

Final Deliverables: Upon completion, you will receive a purified RNA-LNP formulation suitable for immediate use, accompanied by a formal Certificate of Analysis (CoA) and a comprehensive technical report detailing the complete synthesis and characterization process.

Key Advantages

• Integrated Manufacturing Pipeline: We provide end-to-end production services, supporting scalable development from pilot-scale studies through to industrial-scale manufacturing of RNA-LNP formulations.
• Sequence and Expression Optimization: Customized molecular design, including codon, UTR, and regulatory element engineering, ensures robust expression tailored to your target cellular environment or system.
• Native Antigen Presentation: Our platform incorporates engineered signaling and anchoring motifs to ensure proper folding, membrane localization, and immunogenic presentation of complex antigen structures in mammalian systems.

FAQs

Why Choose Us?

Creative Biolabs offers an industry-leading platform that integrates molecular biology with advanced material science. Unlike standard mRNA synthesis providers, we specialize in the "Native" aspect, ensuring that the resulting protein maintains its complex 3D structure and membrane orientation. Our use of Modular Vaccine Platforms allows us to solve translocation issues that often render other RNA vaccines ineffective.

Customer Reviews

How to contact us?

Creative Biolabs provides a specialized Native Antigen-encoded Nanoparticulate RNA Production Service that transforms drug discovery by ensuring high-fidelity, native-state protein expression in vivo. From challenging membrane targets to rapid vaccine prototyping, our integrated workflow and LNP expertise deliver unmatched results.

Furthermore, we offer a variety of innovative solutions based on RNA Vaccine Boosting CAR-T Cell Strategies. These approaches leverage mRNA vaccine technology to further enhance the in vivo expansion, persistence, and anti-tumor activity of CAR-T cells. For detailed project discussions or to receive a custom proposal, please reach out to our scientific team.

Reference

1. Jacob, Eden M et al. "Lipid nanoparticle-based mRNA vaccines: a new frontier in precision oncology." Precision clinical medicine vol. 7,3 pbae017. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1093/pcmedi/pbae017.